Endophthalmitis: Classification and current management

Expert Review of Ophthalmology

Volumn 2, Issue 3, 2007, Pages 385-396

  Schwartz, Stephen G ^a   Flynn jr, Harry W ^a   Scott, Ingrid U ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

endophthalmitis; Endophthalmitis Vitrectomy Study; intravitreal injection; microbial keratitis; toxic anterior segment syndrome

Indexed keywords

EID: 68949126371     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2.3.385     Document Type: Article

References (84)

1. Doft B. Endophthalmitis Management. Focal Points: Modules for Clinicians. American Academy of Ophthalmology, CA, USA (1997).
2. Rosenberg KD, Flynn HW Jr, Alfonso EC, Miller D. Fusarium endophthalmitis following keratitis associated with contact lenses. Ophthalmic Surg. Lasers Imaging 37, 310–313 (2006).
3. Jonas JB, Kreissig I, Spandau UH, Harder B. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol. 141, 579–580 (2006).
4. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch. Ophthalmol. 113, 1479–1496 (1995).
5. Clark WL, Kaiser PK, Flynn HW Jr et al. Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 106, 1665–1670 (1999).
6. Chaudhry NA, Flynn HW Jr, Smiddy WE et al. Xanthomonas maltophilia endophthalmitis after cataract surgery. Arch. Ophthalmol. 188, 572–575 (2000).
7. Scott IU, Lieb DF, Flynn HW Jr et al. Endophthalmitis caused by Mycobacterium chelonae: selection of antibiotics and outcomes of treatment. Arch. Ophthalmol. 121, 573–576 (2003).
8. Song A, Scott IU, Flynn HW Jr, Budenz DL. Delayed-onset bleb-associated endophthalmitis: clinical features and visual acuity outcomes. Ophthalmology 109, 985–991 (2002).
9. Vahey JB, Flynn HW Jr. Results in the management of Bacillus endophthalmitis. Ophthalmic Surg. 22, 681–686 (1991).
10. Schiedler V, Scott IU, Flynn HW Jr et al. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am. J. Ophthalmol. 137 (4), 725–731 (2004).
11. Scott IU, Matharoo N, Flynn HW Jr, Miller D. Endophthalmitis caused by Klebsiella species. Am. J. Ophthalmol. 138, 662–663 (2004).
12. Miller JJ, Scott IU, Flynn HW Jr et al. Endophthalmitis caused by Streptococcus pneumoniae. Am. J. Ophthalmol. 138, 231–236 (2004).
13. Scott IU, Flynn HW Jr, Feuer W et al. Endophthalmitis associated with microbial keratitis. Ophthalmology 103, 1864–1870 (1996).
14. Alfonso EC, Cantu-Dibildox J, Munir WM et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch. Ophthalmol. 124, 941–947 (2006).
15. Chang DC, Grant GB, O’Donnell K et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 296 (8), 953–963 (2006).
16. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens 32, 267–271 (2006).
17. Xie L, Zhong W, Shi W, Sun S. Spectrum of fungal keratitis in north China. Ophthalmology 113, 1943–1948 (2006).
18. Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced Fusarium keratitis progressing to endophthalmitis. Cornea 22, 300–303 (2003).
19. Moshfeghi DM, Kaiser PK, Bakri SJ et al. Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg. Lasers Imaging 36, 24–29 (2005).
20. Lundstrom M, Wejde G, Stenevi U, Thorburn W, Montan P. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 114 (5), 866–870 (2007).
21. Patwardhan A, Rao GP, Saha K, Craig EA. Incidence and outcomes evaluation of endophthalmitis management after phacoemulsification and 3-piece silicone intraocular lens implantation over 6 years in a single eye unit. J. Cataract Refract. Surg. 32, 1018–1021 (2006).
22. Kamalarajah S, Silvestri G, Sharma N et al. Surveillance of endophthalmitis following cataract surgery in the UK. Eye 18, 580–587 (2004).
23. Miller JJ, Scott IU, Flynn HW Jr et al. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am. J. Ophthalmol. 139, 983–987 (2005).
24. Eifrig CWG, Flynn HW Jr, Scott IU, Newton J. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes. Ophthalmic Surg. Lasers 33, 373–378 (2002).
25. West ES, Behrens A, McDonnell PJ et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population increased between 1994 and 2001. Ophthalmology 112, 1388–1394 (2005).
26. Wallin T, Parker J, Jin Y, Kefalopoulos G, Olson RJ. Cohort study of 27 cases of endophthalmitis at a single institution. J. Cataract Refract. Surg. 31, 735–741 (2005).
27. Bucher RS, Hall E, Reed DM et al. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch. Ophthalmol. 123, 649–653 (2005).
28. Taylor SRJ, Aylward GW. Endophthalmitis following 25-gauge vitrectomy. Eye 19, 1228–1229 (2004).
29. Taban M, Ufret-Vincenty RL, Sears JE. Endophthalmitis after 25-gague transconjunctival sutureless vitrectomy. Retina 26 (7), 830–831 (2006).
30. Busbee BG. Endophthalmitis: a reappraisal of incidence and treatment. Curr. Opin. Ophthalmol. 17, 286–291 (2006).
31. Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. Ophthalmology 111, 2015–2022 (2004).
32. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351, 2805–2816 (2004).
33. Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology 133, 633–642 (2006).
34. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (14), 1432–1444 (2006).
35. Rosenfeld PR, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (14), 1419–1431 (2006).
36. Westfall AC, Osborn A, Kuhl D et al. Acute endophthalmitis incidence: intravitreal triamcinolone. Arch. Ophthalmol. 123, 1075–1077 (2005).
37. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol. 90, 1344–1349 (2006).
38. Moshfeghi DM, Kaiser PK, Scott IU et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am. J. Ophthalmol. 136, 791–796 (2003).
39. Aiello LP, Brucker AJ, Chang S et al. Evolving guidelines for intravitreous injections. Retina 24 (5 Suppl.), S3 –S19 (2004).
40. Donahue SP, Kowalski RP, Jewart BH, Friberg TR. Vitreous cultures in suspected endophthalmitis: biopsy or vitrectomy? Ophthalmology 100, 452–455 (1993).
41. Josephberg RG. Endophthalmitis: the latest in current management. Retina 26 (6 Suppl.), S47 –S50 (2006).
42. Hilton GF, Josephberg RG, Halperin LS et al. Office-based sutureless transconjunctival pars plana vitrectomy. Retina 22, 725–732 (2002).
43. Irvine WD, Flynn HW Jr, Murray TG, Rubsamen PE. Retained lens fragments after phacoemulsification manifesting as marked intraocular inflammation with hypopyon. Am. J. Ophthalmol. 114, 610–614 (1992).
44. Mamalis N, Edelhauser HF, Dawson DG, Chew J, LeBoyer RM, Werner L. Toxic anterior segment syndrome. J. Cataract Refract. Surg. 32 (2), 324–333 (2006).
45. Jehan FS, Mamalis N, Spencer TS et al. Postoperative sterile endophthalmitis (TASS) associated with the Memory Lens. J. Cataract Refract. Surg. 26, 1773–1777 (2000).
46. Werner L, Sher JH, Taylor JR et al. Toxic anterior segment syndrome and possible association with ointment in the anterior chamber following cataract surgery. J. Cataract Refract. Surg. 32, 227–235 (2006).
47. Smith CA, Khoury JM, Shields SM et al. Unexpected corneal endothelial decompensation after intraocular surgery with instruments sterilized by plasma gas. Ophthalmology 107, 1561–1566 (2000).
48. Duffy RE, Brown SE, Caldwell KL et al. An epidemic of corneal destruction caused by plasma gas sterilization: the Toxic Endothelial Cell Destruction Syndrome Investigative Team. Arch. Ophthalmol. 188, 1167–1176 (2000).
49. Hellinger WC, Hasan SA, Bacalis LP et al. Outbreak of toxic anterior segment syndrome following cataract surgery associated with impurities in autoclave steam moisture. Infect. Control Hosp. Epidemiol. 27, 294–298 (2006).
50. Liu H, Routley I, Teichmann KD. Toxic endothelial cell destruction from intraocular benzalkonium chloride. J. Cataract Refract. Surg. 27, 1746–1750 (2001).
51. Eleftheriadis H, Cheong M, Sandeman S et al. Corneal toxicity secondary to inadvertent use of benzalkonium chloride preserved viscoelastic material in cataract surgery. Br. J. Ophthalmol. 86, 299–305 (2002).
52. Unal M, Yucel I, Akar Y, Oner A, Altin M. Outbreak of toxic anterior segment syndrome associated with glutaraldehyde after cataract surgery. J. Cataract Refract. Surg. 32, 1696–1701 (2006).
53. Moshfeghi AA, Scott IU, Flynn HW Jr, Puliafito CA. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am. J. Ophthalmol. 138, 489–492 (2004).
54. Nguyen JK, Fung AE, Flynn HW Jr, Scott IU. Hypopyon and pseudoendophthalmitis associated with chronic vitreous hemorrhage. Ophthalmic Surg. Lasers Imaging 37, 317–319 (2006).
55. Schwartz SG, Mieler WF, Holz ER et al. Intravitreal hemoglobin spherulosis: a rare complication of subretinal hemorrhage. Arch. Ophthalmol. 120, 85–87 (2002).
56. Joondeph BC, Flynn HW Jr, Miller D, Joondeph HC. A new culture method for infectious endophthalmitis. Arch. Ophthalmol. 107, 1334–1337 (1989).
57. Anand AR, Madhavan HN, Neela V, Lily T. Use of polymerase chain reaction in the diagnosis of fungal endophthalmitis. Ophthalmology 108, 326–330 (2001).
58. Durand M. Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am. J. Ophthalmol. 124, 127–130 (1997).
59. Doft DH, Wisniewski SR, Kellsy SF et al. Diabetes and postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch. Ophthalmol. 119, 650–656 (2001).
60. Han DP, Wisniewski SR, Wilson LA et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am. J. Ophthalmol. 122, 1–17 (1996).
61. Johnson MW, Doft BH, Kelsey SF et al. The Endophthalmitis Vitrectomy Study: relationship between clinical presentation and microbiologic spectrum. Ophthalmology 104, 261–272 (1997).
62. Hariprasad SM, Mieler WF, Holz ER. Vitreous and aqueous penetration of orally administered gatifloxacin in humans. Arch. Ophthalmol. 121, 345–350 (2004).
63. Park-Wyllie LY, Juurlink DN, Kopp A et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N. Engl. J. Med. 354, 1352–1361 (2006).
64. Iyer MN, Han DP, Yun HJ et al. Subconjunctival antibiotics for acute postcataract extraction endophthalmitis: is it necessary? Am. J. Ophthalmol. 137 (6), 1120–1121 (2004).
65. Smiddy WE, Smiddy RJ, Ba’Arath B et al. Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 25, 751–758 (2005).
66. Bannerman TL, Rhoden DL, McAllister M et al. The source of coagulase-negative staphylococci in the Endophthlamitis Vitrectomy Study: a comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch. Ophthalmol. 115, 357–361 (1997).
67. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 109, 13–26 (2002).
68. Montan PG, Wejde G, Koranyi G, Rylander M. Prophylactic intracameral cefuroxime: efficacy in preventing endophthalmitis after cataract surgery. J. Cataract Refract. Surg. 28, 977–981 (2002).
69. Barry P, Seal DV, Gettinby G et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a European multicenter study. J. Cataract Refract. Surg. 32, 407–410 (2006).
70. Busbee BG, Recchia FM, Kaiser R et al. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology 111, 1495–1503 (2004).
71. Busbee BG. Update on treatment strategies for bleb-associated endophthalmitis. Curr. Opin. Ophthalmol. 16, 170–174 (2005).
72. Pflugfelder SC, Hernandez E, Fliesler SJ et al. Intravitreal vancomycin. Retinal toxicity, clearance, and interaction with gentamicin. Arch. Ophthalmol. 105, 831–837 (1987).
73. Pavan PR, Oteiza EE, Hughes BA, Avni A. Exogenous endophthalmitis initially treated without systemic antibiotics. Ophthalmology 101, 1289–1296 (1994).
74. Kazi AA, Jermak CM, Peyman GA, Aydin E, Riazi-Esfahani M. Intravitreal toxicity of levofloxacin and gatifloxacin. Ophthalmic Surg. Lasers Imaging 37, 224–229 (2006).
75. Gao H, Pennesi ME, Qiao X et al. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest. Ophthalmol. Vis. Sci. 47, 1606–1611 (2006).
76. Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina 26, 187–190 (2006).
77. Esfahani MR, Kazi AA, Peyman GA, Dellacroce JT, Aydin E. Intravitreal toxicity of garenoxacin. Retina 26, 182–186 (2006).
78. Lakhanpal RR, Humayun MS, de Juan E Jr et al. Outcomes of 140 consecutive cases of 25-gauge transconjunctival surgery for posterior segment disease. Ophthalmology 112, 817–824 (2005).
79. Yanyali A, Celik E, Horozoglu F, Oner S, Nohutcu AF. 25-gauge transconjunctival sutureless pars plana vitrectomy. Eur. J. Ophthalmol. 16 (1), 141–147 (2006).
80. Van Limbergen J, Kalima P, Taheri S, Bettie TF. Streptococcus A in paediatric accident and emergency: are rapid streptococcal tests and clinical examination of any help? Emerg. Med. J. 23, 32–34 (2006).
81. Sambursky R, Tauber S, Schirra F, Kozich K, Davidson R, Cohen EJ. The RPS Adeno Detector for diagnosing adenoviral conjunctivits. Ophthalmology 113, 1758–1764 (2006).
82. Holz ER. Reducing endophthalmitis risk factors: where we stand. Am. J. Ophthalmol. 139, 1097–1098 (2005).
83. Taban M, Sarayba MA, Ignacio TS, Behrens A, McDonnell PJ. Ingress of India ink into the anterior chamber through sutureless clear corneal cataract wounds. Arch. Ophthalmol. 123 (5), 643–648 (2005).
84. Stewart JM. Wound integrity and the conjunctiva in prevention of endophthalmitis following sutureless 25-gauge vitrectomy. Eye 20 (12), 1490 (2006).